Results 11 to 20 of about 5,736 (192)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +2 more sources

A pilot trial of deferiprone for neurodegeneration with brain iron accumulation [PDF]

Haematologica, 2011
Deferiprone was shown to reverse iron deposition in Friedreich’s ataxia. This multi-center, unblinded, single-arm pilot study evaluated safety and efficacy of deferiprone for reducing cerebral iron accumulation in neurodegeneration with brain iron ...
Giovanni Abbruzzese, Giovanni Cossu, Manuela Balocco, Roberta Marchese, Daniela Murgia, Maurizio Melis, Renzo Galanello, Susanna Barella, Gildo Matta, Uberto Ruffinengo, Ubaldo Bonuccelli, Gian Luca Forni   +11 more
doaj   +2 more sources

Amphetamine-like Deferiprone and Clioquinol Derivatives as Iron Chelating Agents [PDF]

Molecules
The accumulation of iron in dopaminergic neurons can cause oxidative stress and dopaminergic neuron degeneration. Iron chelation therapy may reduce dopaminergic neurodegeneration, but chelators should be targeted towards dopaminergic cells. In this work,
Mahmoud El Safadi, Katie A. Wilson, Indigo J. Strudwicke, Megan L. O’Mara, Mohan Bhadbhade, Tristan Rawling, Andrew M. McDonagh   +6 more
doaj   +3 more sources

Chitogel with deferiprone following endoscopic sinus surgery: improved wound healing and microbiome [PDF]

Frontiers in Surgery
BackgroundAdhesion formation, sinus ostial narrowing, and presence of pathogenic bacteria are associated with poor outcomes following endoscopic sinus surgery (ESS) for chronic rhinosinusitis.
Anna Megow, George Bouras, Yazeed Alsuliman, Clare Cooksley, Erich Vyskocil, William Murphy, Sarah Vreugde, Peter-John Wormald   +7 more
doaj   +2 more sources

Comparative Efficacy of Deferiprone, Deferoxamine and Combination of Deferiprone and Deferoxamine on Serum Ferritin Value in Beta-Thalassemia Patients [PDF]

Journal of Krishna Institute of Medical Sciences University, 2015
Background: Iron overload is a predictable and lifethreatening complication in patients with thalassemia. Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major.
Nargesbeygom Mirbehbahani , Azam Jahazi, Haniye Mohsenkhah Amlashi, Naser Behnampour   +3 more
doaj   +2 more sources

Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series

Infectious Disease Reports, 2018
Mucormycosis is a life-threatening disease requiring multimodal treatment with antifungals and surgery. The mortality rate remains high, prompting consideration of alternative treatment strategies. Deferiprone has in vitro activity against Mucorales, but
Maria N. Chitasombat, Pimjai Niparuck
doaj   +3 more sources

Luspatercept in Transfusion-Dependent Thalassemia With Red Blood Cell Antibodies: A Case Series. [PDF]

EJHaem
ABSTRACT Red blood cell (RBC) antibodies complicate transfusion support in transfusion‐dependent thalassemia (TDT), and data on luspatercept in this setting remain limited. We retrospectively reviewed seven adults with TDT and RBC antibodies treated with luspatercept at Srinagarind Hospital from January 2025 to January 2026.
Teawtrakul N.
europepmc   +2 more sources

Trial of Deferiprone in Parkinson's Disease

, 2022
BACKGROUND: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder.
Devos, D., Dušek, Petr, Habert, M.O., Post, Bart, Meissner, Wassilios G., Habert, Marie-Odile, Labreuche, J., Bordet, Régis, Pruvo, J.P., Leclercq, C., Bush, Ashley I, Dodel, R., Poewe, W., Tricta, F., Leclercq, C. line, Marques, A.R., Pavese, Nicola, Bloem, Bastiaan R., Viard, Romain, Rolland, A.S., Scherfler, Christoph, Deplanque, D., Fradette, Caroline, Meissner, W.G., Vilas, D., Maetzler, Walter, Kuchcinski, G., Tranchant, Christine, Dušek, P., Růžička, E., Dexter, D.T., Otto, Markus, Corvol, Jean-Christophe, Moreau, Caroline, Bloem, Bastiaan R, Ruzička, EvÅen, Kulisevsky, J., Carpentier, J., Guyon Delannoy, Pauline, de Bie, Rob M.A., Rascol, O., Moreau, C., Coelho, Miguel V.S., Compta, Yaroslau, Spino, Michael, Januario, Cristina, Kuchcinski, Gregory, Duce, James A, Bush, Ashley I., Worth, Paul, Nyholm, Dag, Seppi, K., Garçon, G., Pigny, P., Maetzler, W., Gago, Miguel, Mangin, Jean-François, Leclercq, Céline, Lehericy, S., Ory-Magne, Fabienne, Ory-Magne, F., Behnke, S., Mangin, J.F., Ferreira, Joaquim, Walter, U., Simonin, O., Duhamel, Alain, Eusebio, A., Corvol, J.C., Devedjian, Jean-Christophe, Rascol, Olivier, Coelho, Miguel V S, Dexter, David T., Pruvo, Jean-Pierre, Pigny, Pascal, Duhamel, A., Walter, Uwe, Ferreira, J., Bordet, R., Chupin, M., Viard, R., Pavese, N., Vilas, Dolores, Simonin, Ophélie, Post, B., Potey, C., Ayton, S., Bush, A.I., Duce, J.A., Devos, David, Růžička, Evžen, Fradette, C., Compta, Y., Tricta, Fernando, Berg, D., Tranchant, C., Berg, Daniela, Ayton, Scott, Lehericy, Stéphane, Deplanque, Dominique, Devedjian, J.C., Cabantchik, I., Dodel, Richard, Delannoy, P. Guyon, Garçon, Guillaume, Labreuche, Julien, Poewe, Werner, Thobois, Stéphane, Januario, C., Lopes, Renaud, Ouk, Thavarak, Coelho, M.V.S., Meissner, Wassilios G, Scherfler, C., Lopes, R., Spino, M., Otto, M., Chupin, Marie, Eusebio, Alexandre, Defebvre, Luc, Barone, P, de Bie, Rob M. A., de Bie, Rob M A, Nyholm, Dag,, Defebvre, L., Behnke, Stefanie, Seppi, Klaus, Kulisevsky, Jaime, Ouk, T., Bloem, B.R., Bie, R.M. de, Cabantchik, Ioav, Dexter, David T, Bordet, R. gis, Carpentier, Jessica, Thobois, S., Coelho, Miguel V. S., Worth, P., Duce, James A., Delannoy, Pauline Guyon, Gago, M., Rolland, Anne-Sophie, Marques, Ana-Raquel, Nyholm, D., Potey, Camille   +144 more
core   +1 more source

Hematological Parameters in Beta Thalassemia Major Children [PDF]

Minia Journal of Medical Research, 2022
Background: Thalassemia is a hematological disorder that is caused by mutations in the genes that encode hemoglobin chains. Mutations in the β-globin gene are the most common cause of genetic disorders in humans, with 350 β-thalassemia variants ...
Zamzam Mohamed, Doaa Ismail, Samira Sayed, Arwa Aziz   +3 more
doaj   +1 more source

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

Haematologica, 2011
Background Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially available but its long-term efficacy on cardiac iron and ...
Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, Aurelio Maggio   +19 more
doaj   +1 more source